Recent Quotes

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

Earnings

Q2 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-08-10
REV		(EXPECTED)2021-08-10

Q1 2021		Est.		Actual		Surprise
EPS		-0.720		-0.760		-0.0400
REV				0

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Related Companies

Ticker	Company	Price	Change	Chg %		Mkt Cap
LRMR	Larimar Therapeutics	8.26	-0.73	-8.12%		178.4M

Larimar Therapeutics Frequently Asked Questions

How do I buy Larimar Therapeutics (LRMR) stock?

You can purchase shares of Larimar Therapeutics (NASDAQ: LRMR) through any online brokerage.

View our list of the best stock brokerages.

Who are Larimar Therapeutics's (LRMR) competitors?

Other companies in Larimar Therapeutics’s space includes: Calithera Biosciences (NASDAQ:CALA), NuCana (NASDAQ:NCNA), BioLine Rx (NASDAQ:BLRX), La Jolla Pharmaceutical (NASDAQ:LJPC) and Concert Pharmaceuticals (NASDAQ:CNCE).

What is the target price for Larimar Therapeutics (LRMR) stock?

The latest price target for Larimar Therapeutics (NASDAQ: LRMR) was reported by William Blair on February 1, 2021. The analyst firm set a price target for 0.00 expecting LRMR to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.

Current Stock Price for Larimar Therapeutics (LRMR)?

The stock price for Larimar Therapeutics (NASDAQ: LRMR) is $8.99 last updated Wed Jun 23 2021 20:00:02 GMT+0000 (Coordinated Universal Time).

Does Larimar Therapeutics (LRMR) pay a dividend?

There are no upcoming dividends for Larimar Therapeutics.

When is Larimar Therapeutics (NASDAQ:LRMR) reporting earnings?

Larimar Therapeutics’s Q2 earnings are confirmed for after-market on August 10, 2021.

Is Larimar Therapeutics (LRMR) going to split?

There is no upcoming split for Larimar Therapeutics.

What sector and industry does Larimar Therapeutics (LRMR) operate in?

Larimar Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.